Company intelligence / Profile preview

AesculaTech

Los Angeles, California, United Statesaesculatech.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

The company has developed a temperature-responsive smart material called AesculaGel that functions as a punctal plug for dry eye treatment. It's applied as a liquid and solidifies at body temperature to block tear ducts. The company is preparing for a larger human clinical trial before FDA submission[5].

Therapeutic areas: Ophthalmology
Modalities: Smart materialsHydrogels
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Humidifeye

Pre-clinical

Indications: Dry eye disease

Partnerships

Mentioned as partnering with industry leaders, but specific companies not named[2]

Beyond the preview

Go deeper on AesculaTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AesculaTech.

Explore the full profile